Evidence brief
Insulin
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
Several FDA-approved insulin products exist, including highly similar versions called biosimilars.
Insulin is a family of diabetes medicines. Different products can have different timing, risks, and instructions.
- How strong is the evidence?
- Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone. - What evidence exists?
- Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result. - Sports rules
- Prohibited
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed August 30, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Related insulin terms human insulin · insulin analog · rapid-acting insulin · basal insulin
Part of Metabolic peptide medicines
Words used here
- outcome
- what the study measured
- analog
- a changed version made to act like another substance
- randomized
- assigned to study groups by chance
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Long-term studies that assigned people to groups by chance support closely monitored insulin treatment for specific groups with diabetes.
Studies describe when each product starts working, reaches its strongest effect, and wears off.
Product labels and many years of use describe the main risks, especially dangerously low blood sugar.
High when the product is a real approved product. The exact product and its ingredients still matter.
02 · Identity
What it is
“Insulin” does not name one single product. It is a hormone made by the pancreas. It is also the name for a family of diabetes medicines. Products may be rapid-acting, short-acting, intermediate-acting, long-acting, or mixed. These products have different timing, risks, and instructions.
Scientific group: Peptide hormone · family of protein medicines. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
Humalog
May 2025- Formulation
- Several strengths and delivery forms listed in the label
- Route
- Injection under the skin. Humalog U-100 can also be used in some insulin pumps. Its label allows medical staff to give the U-100 form through a vein after dilution and with close monitoring. The U-200 form must not be used through a vein.
- Indication scope
- Diabetes treatment for the people and uses listed in the current Humalog label. This example does not describe every insulin product.
- Multiple human insulin and insulin analog products
- Diabetes treatment for the people listed in each product's label
04 · Research results
What the research shows
The Diabetes Control and Complications Trial (DCCT) put 1,441 people with type 1 diabetes into groups by chance. It compared an intensive insulin plan with a less intensive plan. It followed them for about 6.5 years. The intensive plan lowered the risk of new or worsening eye, kidney, and nerve problems. It also led to two to three times as many severe low-blood-sugar events. Insulin is essential for type 1 diabetes. Insulin treats other forms of diabetes too.
One insulin plan is not right for everyone. Products, schedules, targets, and treatment levels vary by person and product. Evidence for one product, group, or plan does not support switching products on your own. It also does not show that every product can be exchanged freely or used for non-medical reasons.
Exact product
The name insulin covers many FDA-approved products. They can differ in the amount of medicine, how long they work, how they enter the body, and what their labels allow.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Insulin is an established treatment for diabetes.”
Several insulin products have FDA approval. Long-term studies in people support closely monitored insulin plans for specific groups with diabetes. The exact product and care setting still matter.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- FDA-approved insulin products and closely monitored treatment plans for specific groups with diabetes. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“All insulin products work the same way and can be swapped freely.”
Insulin products can differ in how fast they work and how much medicine they contain. They can also differ in how they enter the body and what their FDA labels allow. Some biosimilars can be substituted under state law. This does not make every insulin product freely exchangeable.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The exact insulin products, amounts of medicine, ways to give them, and labels reviewed. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“More intensive insulin treatment is always better.”
The DCCT found fewer long-term complications with an intensive plan. It also found about two to three times as many severe low-blood-sugar events. The right treatment level differs by person and needs medical monitoring.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- The specific intensive plan and people with type 1 diabetes studied in the DCCT. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Insulin
Several FDA-approved insulin products exist, including highly similar versions called biosimilars. Approved products identified: Multiple human insulin and insulin analog products.
Prohibited. The 2026 WADA list prohibits insulin at all times for athletes it covers, unless an applicable therapeutic-use exemption allows it. This status is not personal clearance to compete.
The Diabetes Control and Complications Trial (DCCT) put 1,441 people with type 1 diabetes into groups by chance. It compared an intensive insulin plan with a less intensive plan. It followed them for about 6.5 years. The intensive plan lowered the risk of new or worsening eye, kidney, and nerve problems. It also led to two to three times as many severe low-blood-sugar events. Insulin is essential for type 1 diabetes. Insulin treats other forms of diabetes too.
One insulin plan is not right for everyone. Products, schedules, targets, and treatment levels vary by person and product. Evidence for one product, group, or plan does not support switching products on your own. It also does not show that every product can be exchanged freely or used for non-medical reasons.
07 · Safety
Safety limits for this record
Hypoglycemia means dangerously low blood sugar. It can be severe and life-threatening. Product mix-ups and changes without medical guidance can cause serious harm. This guide does not give dose calculations, correction factors, injection steps, or advice for changing an insulin plan.
The 2026 WADA list prohibits insulin at all times for athletes it covers, unless an applicable therapeutic-use exemption allows it.
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed .Check current rules for tested sport ↗Open the governing record ↗08 · Sources
Read the sources
09 · Review history
Review history
Checked the current Humalog label, the main DCCT results, and the 2026 WADA rule for insulin. Kept the product and study limits.
Expanded product, safety, and claim source details.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.